These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 34755133

  • 1. Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis.
    Ferrian S, Liu CC, McCaffrey EF, Kumar R, Nowicki TS, Dawson DW, Baranski A, Glaspy JA, Ribas A, Bendall SC, Angelo M.
    Cell Rep Med; 2021 Oct 19; 2(10):100419. PubMed ID: 34755133
    [Abstract] [Full Text] [Related]

  • 2. Immune Checkpoint Inhibitor-Induced Upper Gastrointestinal Tract Inflammation Shows Morphologic Similarities to, but Is Immunologically Distinct From, Helicobacter pylori Gastritis and Celiac Disease.
    Irshaid L, Robert ME, Zhang X.
    Arch Pathol Lab Med; 2021 Feb 01; 145(2):191-200. PubMed ID: 33501492
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Nivolumab-associated active neutrophilic gastritis.
    Rovedatti L, Lenti MV, Vanoli A, Feltri M, De Grazia F, Di Sabatino A.
    J Clin Pathol; 2020 Sep 01; 73(9):605-606. PubMed ID: 32161070
    [No Abstract] [Full Text] [Related]

  • 6. Acute Ulceronecrotic Gastritis With Cytomegalovirus Reactivation: Uncommon Toxicity of Immune Checkpoint Inhibitors in Microsatellite Instability-High Metastatic Colorectal Cancer.
    Hulo P, Touchefeu Y, Cauchin E, Archambeaud I, Chapelle N, Bossard C, Bennouna J.
    Clin Colorectal Cancer; 2020 Dec 01; 19(4):e183-e188. PubMed ID: 32703755
    [No Abstract] [Full Text] [Related]

  • 7. Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma.
    Xiong Y, Neskey DM, Horton JD, Paulos CM, Knochelmann HM, Armeson KE, Young MRI.
    BMC Cancer; 2020 Mar 17; 20(1):229. PubMed ID: 32183719
    [Abstract] [Full Text] [Related]

  • 8. A Case of Severe Acute Gastritis as an Immune-Related Adverse Event After Nivolumab Treatment: Endoscopic and Pathological Findings in Nivolumab-Related Gastritis.
    Ebisutani N, Tozawa K, Matsuda I, Nakamura K, Tamura A, Hara K, Kondo T, Terada T, Tomita T, Oshima T, Fukui H, Hirota S, Miwa H.
    Dig Dis Sci; 2021 Jul 17; 66(7):2461-2465. PubMed ID: 32780186
    [No Abstract] [Full Text] [Related]

  • 9. Downregulated regulatory T cell function is associated with increased peptic ulcer in Helicobacter pylori-infection.
    Bagheri N, Shirzad H, Elahi S, Azadegan-Dehkordi F, Rahimian G, Shafigh M, Rashidii R, Sarafnejad A, Rafieian-Kopaei M, Faridani R, Tahmasbi K, Kheiri S, Razavi A.
    Microb Pathog; 2017 Sep 17; 110():165-175. PubMed ID: 28666843
    [Abstract] [Full Text] [Related]

  • 10. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G, Shen T, Yan C, Zhang M, Wu Z, Cao L.
    BMC Cancer; 2019 Nov 06; 19(1):1053. PubMed ID: 31694582
    [Abstract] [Full Text] [Related]

  • 11. Local cellular immune response in Helicobacter pylori associated type B gastritis--selective increase of CD4+ but not gamma delta T-cells in the immune response to H. pylori antigens.
    Seifarth C, Deusch K, Reich K, Classen M.
    Z Gastroenterol; 1996 Apr 06; 34(4):215-24. PubMed ID: 8686348
    [Abstract] [Full Text] [Related]

  • 12. Essential role of Peyer's patches in the development of Helicobacter-induced gastritis.
    Kiriya K, Watanabe N, Nishio A, Okazaki K, Kido M, Saga K, Tanaka J, Akamatsu T, Ohashi S, Asada M, Fukui T, Chiba T.
    Int Immunol; 2007 Apr 06; 19(4):435-46. PubMed ID: 17314082
    [Abstract] [Full Text] [Related]

  • 13. Severe steroid refractory gastritis induced by Nivolumab: A case report.
    Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H.
    World J Gastroenterol; 2020 Apr 28; 26(16):1971-1978. PubMed ID: 32390707
    [Abstract] [Full Text] [Related]

  • 14. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
    Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, Kluger HM, Gettinger SN, Sznol M, Tykodi SS, Curti BD, Tagliaferri MA, Zalevsky J, Hannah AL, Hoch U, Aung S, Fanton C, Rizwan A, Iacucci E, Liao Y, Bernatchez C, Hurwitz ME, Cho DC.
    Cancer Discov; 2020 Aug 28; 10(8):1158-1173. PubMed ID: 32439653
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.
    Heeren AM, Rotman J, Stam AGM, Pocorni N, Gassama AA, Samuels S, Bleeker MCG, Mom CH, Zijlmans HJMAA, Kenter GG, Jordanova ES, de Gruijl TD.
    J Immunother Cancer; 2019 Feb 12; 7(1):43. PubMed ID: 30755279
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice.
    Smythies LE, Waites KB, Lindsey JR, Harris PR, Ghiara P, Smith PD.
    J Immunol; 2000 Jul 15; 165(2):1022-9. PubMed ID: 10878379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.